Amoy Diagnostics (SHE:300685) amended the registration certificate of its PD-L1 Antibody Reagent (Immunohistochemistry) product, according to a Shenzhen Stock Exchange disclosure on Thursday.
The Chinese diagnostic company changed the product's use, stating that the kit is used for in vitro qualitative detection of PD-L1 protein expression in 10% neutral buffered formalin fixed paraffin embedded gastric/gastroesophageal adenocarcinoma in patients who can be treated with sugemalimab combined with chemotherapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.